Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794309 | 0.92 | PDE10A (0.53) | PDE10AKDRFLT1FGFR1KDM1A | |
| SCHEMBL5651018 | 0.92 | PDE10A (0.54) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL14367677 | 0.92 | PDE10A (0.54) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4978026 | 0.88 | PDE10A (0.53) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4971347 | 0.87 | PDE10A (0.49) | PDE10APDGFRB | |
| SCHEMBL4173257 | 0.85 | PDE10A (0.50) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4971821 | 0.85 | PDE10A (0.46) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL5652797 | 0.84 | PDE10A (0.65) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL14367679 | 0.84 | PDE10A (0.65) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4973098 | 0.83 | PDE10A (0.61) | PDE10ACYP2D6GSK3BPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | PDE10A 3/4885KDR 4714/4885FLT1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.